Business
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2024.
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase","length":89,"tagName":"p","attribs":{}},{"type":"text","content":"Recognized EsoGuard revenue of $1.2 million in 4Q24 ","length":52,"tagName":"p","attribs":{}},{"type":"text","content":"New sales channel generated over 20 new cash-pay concierge medicine contracts","length":77,"tagName":"p","attribs":{}},{"type":"text","content":"Secured first agreement to pay for EsoGuard under state biomarker legislation","length":77,"tagName":"p","attribs":{}},{"type":"text","content":"Conference call and webcast to be held today, March 24th at 8:30 AM EDT","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, March 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2024.","length":423,"tagName":"p"},{"type":"image","alt":"Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)","displaySize":"","headline":null,"caption":"Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":107,"url":"https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EIajbOKjadbArgiAenSE8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c","width":400,"height":107}},"href":"https://mma.prnewswire.com/media/2003008/Lucid_TM_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Conference Call and Webcast","length":27,"tagName":"p"},{"type":"text","content":"T...